Exhibit 99.1
SurModics Reports First Quarter Results
Record Revenue and Earnings
EDEN PRAIRIE, Minnesota — January 26, 2005 — SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the medical device industry, today reported financial results for the first quarter ended December 31, 2004.
First Quarter Highlights:
| • | Record Revenue of $14.1 million |
| |
| • | R&D Revenue Growth for Fourth Consecutive Quarter |
| |
| • | Operating Income of $8.6 million; Operating Margin of 61% |
| |
| • | Record Net Income of $5.7 million |
| |
| • | Record Diluted EPS of $.32 |
“SurModics is pleased to report record revenue and earnings for the first quarter,” said Dale Olseth, Chairman and CEO. “Particularly gratifying is the broad-based contribution to this growth coming from a number of our customers.”
Revenue for the first quarter of fiscal 2005 was a record $14.1 million, an increase of 16% from $12.1 million in fiscal 2004. Operating income grew 37% to a record $8.6 million, from $6.3 million in the prior-year period. Net income increased 38% to a record $5.7 million, from $4.1 million in the same period last year. Diluted earnings per share was a record $.32, compared with $.23 in fiscal 2004.
“We continue to execute on our revenue growth plan and are encouraged by the level of customer interest in SurModics’ growing portfolio of surface modification and drug delivery technologies,” said Bruce Barclay, President and COO. “We believe the continued growth in research and development revenue this quarter — the fourth consecutive quarter of sequential growth — speaks to the relevance of our technologies for our customers.”
SurModics First Quarter 2005 Results
Page 2
“We are also pleased with the growth Cordis has achieved with its CYPHER stent,” Barclay continued. “Their reported sales of CYPHER of $561 million for the December quarter reflects a 28% growth sequentially from the September quarter. We are particularly delighted with their results in Japan, where we expect Cordis to have the only drug eluting stent available until the second half of 2006.”
SurModics’ pipeline continues to expand. The Company signed four new licenses in the first quarter, making good progress toward our goal of 12 new licenses for fiscal 2005. At December 31, SurModics’ customers had 80 coated products generating royalty revenue, compared with 70 in the prior-year period; the total number of licensed products not yet launched was 63, unchanged from a year ago; and major non-licensed opportunities increased to 68, from 33 a year ago. In total, the Company now has 131 potential commercial products in development with opportunities in each of the company’s four focus markets - ophthalmology, cardiovascular, neurology and orthopedics.
“We are in excellent financial condition,” said Phil Ankeny, CFO and Vice President of Business Development. “Our balance sheet remains strong, with a cash and investment balance of $61.8 million and no debt as of December 31. We are pleased with our continued progress putting the balance sheet to work. The two transactions we announced last week — our investment in OctoPlus and our acquisition of InnoRx — position us well strategically.”
Live Webcast
SurModics will host a Webcast at 5:00 p.m. ET (4:00 p.m. CT) today to discuss the quarterly results. To access the Webcast, go to the investor relations portion of the company’s web site, www.surmodics.com, and click on the first quarter webcast icon. If you do not have access to the Internet and want to listen to the audio, dial 800-366-7449. A replay of the first quarter conference call, will be available by dialing 800-405-2236 and entering conference call ID 11022149. The audio replay will be available beginning at 6:00 p.m. CT on Wednesday, January 26, until 5:00 p.m. CT on Wednesday, February 2.
SurModics First Quarter 2005 Results
Page 3
About SurModics, Inc.
SurModics, Inc., a leading provider of surface modification and drug delivery solutions, licenses its proprietary technologies to medical device, diagnostics, and biotechnology companies around the world. A significant portion of SurModics’ revenue is generated through royalties on the sale of coated products. SurModics’ Internet address iswww.surmodics.com.
Safe Harbor for Forward Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Phil Ankeny, Chief Financial Officer and Vice President, Business Development (952) 829-2700
SurModics First Quarter 2005 Results
Page 4
SurModics, Inc.
Statements of Income
(In thousands, except per share data)
| | | | | | | | | |
| | | Three Months Ended | |
| | | December 31, | |
| | | 2004 | | | 2003 | |
| | | (Unaudited) | |
Revenue: | | | | | | | | |
Royalties and license fees | | $ | 10,091 | | | $ | 8,629 | |
Product sales | | | 2,000 | | | | 2,600 | |
Research & development | | | 1,978 | | | | 858 | |
| | | | | | | |
Total revenue | | | 14,069 | | | | 12,087 | |
Operating expenses: | | | | | | | | |
Product | | | 620 | | | | 736 | |
Research & development | | | 3,355 | | | | 3,271 | |
Sales & marketing | | | 262 | | | | 418 | |
General & administrative | | | 1,194 | | | | 1,375 | |
| | | | | | | |
Total operating expenses | | | 5,431 | | | | 5,800 | |
| | | | | | | |
Income from operations | | | 8,638 | | | | 6,287 | |
Investment income | | | 417 | | | | 295 | |
| | | | | | | |
Income before income taxes | | | 9,055 | | | | 6,582 | |
Income tax provision | | | (3,373 | ) | | | (2,471 | ) |
| | | | | | | |
Net income | | $ | 5,682 | | | $ | 4,111 | |
| | | | | | | |
Basic net income per share | | $ | 0.32 | | | $ | 0.24 | |
| | | | | | | |
Diluted net income per share | | $ | 0.32 | | | $ | 0.23 | |
| | | | | | | |
Weighted average shares outstanding | | | | | | | | |
Basic | | | 17,574 | | | | 17,454 | |
Diluted | | | 17,950 | | | | 17,766 | |
- more -
SurModics First Quarter 2005 Results
Page 5
SurModics, Inc.
Condensed Balance Sheets
(In thousands)
| | | | | | | | | |
| | | December 31, | | | September 30, | |
| | | 2004 | | | 2004 | |
| | | (Unaudited) | | | | | |
Assets | | | | | | | | |
Current assets: | | | | | | | | |
Cash & investments | | $ | 13,484 | | | $ | 19,215 | |
Accounts receivable | | | 9,497 | | | | 8,130 | |
Inventories | | | 1,105 | | | | 1,040 | |
Other current assets | | | 1,184 | | | | 1,184 | |
| | | | | | | |
Total current assets | | | 25,270 | | | | 29,569 | |
Property & equipment, net | | | 15,299 | | | | 15,738 | |
Long-term investments | | | 48,349 | | | | 44,088 | |
Other assets | | | 21,781 | | | | 20,386 | |
| | | | | | | |
Total assets | | $ | 110,699 | | | $ | 109,781 | |
| | | | | | | |
Liabilities & Stockholders’ Equity | | | | | | | | |
Total current liabilities | | $ | 6,764 | | | $ | 11,789 | |
Other liabilities | | | 3,573 | | | | 3,488 | |
Total stockholders’ equity | | | 100,362 | | | | 94,504 | |
| | | | | | | |
Total liabilities & stockholders’ equity | | $ | 110,699 | | | $ | 109,781 | |
| | | | | | | |
# # #
